Welcome to our dedicated page for Masimo news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo stock.
Masimo Corporation (MASI) delivers innovative noninvasive monitoring technologies and premium audio solutions across global markets. This news hub provides investors and industry professionals with timely updates directly from corporate communications and verified financial sources.
Access official press releases covering Masimo's healthcare innovations, including sensor technology advancements and hospital automation systems, alongside developments in its consumer audio division. Our repository tracks regulatory filings, partnership announcements, and clinical validation studies while maintaining strict editorial neutrality.
Key updates include quarterly earnings disclosures, product launch details across both business segments, and strategic corporate actions. Bookmark this page for streamlined monitoring of Masimo's operational milestones and market-moving events in the medical technology sector.
Masimo (NASDAQ: MASI) announced results from a study published in the Journal of Cardiothoracic and Vascular Anesthesia showing that using SedLine Brain Function Monitoring during cardiac surgeries significantly reduces the need for vasoactive and inotropic drugs. The study involved 300 patients from the Montreal Heart Institute. Key findings included a 57% reduction in higher vasoactive and inotropic scores, shorter mechanical ventilation duration, less intraoperative bleeding, and lower fluid requirements. However, pEEG-guided anesthesia did not improve CPB separation outcomes. Further prospective studies are recommended.
Masimo (NASDAQ: MASI) reported findings that Masimo SafetyNet®, a remote patient management solution, significantly reduced mortality rates among COVID-19 patients. A study published in JAMA indicates that at-home monitoring could decrease deaths by 77% and hospitalizations by 87%. The study emphasizes patient-centered monitoring rather than location-based care, using advanced technologies like Masimo SET® pulse oximeters. The findings support the potential of remote monitoring to transform healthcare delivery.
Masimo (NASDAQ: MASI) has completed its acquisition of Sound United, a prominent consumer technology company known for its premium audio and home entertainment brands such as Bowers & Wilkins and Denon. This acquisition is expected to enhance Masimo's portfolio by integrating Sound United's established consumer channels with its advanced medical technologies. The division will maintain its current leadership and headquarters in Carlsbad, California. Financial impacts will be discussed during Masimo's first quarter earnings release on May 3, 2022.
Masimo Corporation (NASDAQ: MASI) announced preliminary financial results for Q1 2022, expecting product revenue between
Supply chain issues, including critical component shortages and freight delays, led to lower-than-expected sales. The company reaffirmed its full-year revenue guidance of
Masimo (NASDAQ: MASI) announced findings from a study indicating that children monitored with SpHb® experience fewer blood transfusions, less bleeding, and shorter ICU stays during fronto-orbital advancement surgery. The study, published in the Journal of Clinical Monitoring and Computing, analyzed data from 42 pediatric patients, revealing that the SpHb monitoring group had significantly lower intraoperative packed red blood cell transfusion (136.3 mL vs. 181.5 mL, p = 0.015), less postoperative surgical site drainage, and shorter ICU stays (37.1 hours vs. 64.8 hours, p < 0.001).
Masimo (NASDAQ: MASI) has expanded its Patient SafetyNet™ platform, introducing secure telehealth capabilities at the HIMSS Global Health Conference. This enhancement facilitates end-to-end audio and visual communication for remote patient monitoring, improving clinical workflows and communication efficiency. The software upgrade integrates multi-way communication, allowing real-time collaboration among clinicians. Additionally, it supports remote access to continuous patient monitoring data and enhances patient engagement by enabling virtual consultations with family members at the bedside, ultimately aiming to improve patient outcomes and reduce care costs.
Masimo has received FDA clearance for its SedLine brain function monitoring technology for pediatric patients aged 1-17 in the United States. This advancement allows for enhanced monitoring of brain activity during anesthesia, with specialized sensors designed for smaller foreheads. The SedLine system utilizes advanced signal processing of EEG signals to provide detailed insights for clinicians, aiming to improve safety and efficacy during pediatric anesthesia.
Sound United, a leader in premium audio products, has agreed to be acquired by Masimo (NASDAQ: MASI), a global medical technology company. This strategic acquisition aims to combine Masimo's healthcare strengths with Sound United's consumer electronics expertise, enhancing product distribution and consumer experience. The partnership will utilize Sound United’s extensive brand portfolio and global reach to improve Masimo's consumer product offerings. The transaction is anticipated to close in mid-2022, pending regulatory approvals.
Masimo reported a 11.0% increase in product revenue for Q4 2021, totaling $327.6 million, and an 8.3% increase for the full year, reaching $1,239.2 million. GAAP net income for Q4 was $68.3 million or $1.18 per diluted share, while full-year GAAP net income stood at $229.6 million, $3.98 per share. 2022 guidance estimates product revenue at $1,350 million. Additionally, Masimo plans to acquire Sound United for approximately $1.025 billion, expected to bolster their consumer health technology strategy.
Masimo (NASDAQ: MASI) has expanded its Masimo SafetyNet platform to incorporate advanced telehealth capabilities, allowing for robust video-based virtual consultations alongside continuous remote monitoring. This update enhances patient care by enabling clinicians to perform multi-way virtual appointments through a single smartphone app, integrating vital sign monitoring and enhanced communication tools. The platform now supports a wider range of patients, including post-surgical and chronic condition cases, streamlining care from hospital to home.